

UNITED STATES DEPARTMENT OF COMMERCE **Patent and Trademark Office**

COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 Address:

	APPLICATION NO.	FILING DATE	FIRST NAME	D INVENTOR		ATTORNEY DOCKET NO.
	09/117,586	07/31/98	BAILEY		S	87647.98R199
Γ	_		IM31/0422	, ¬	EXAMINER	
	SUSAN J BRAMAN				PRATT.	-1
	BRAMAN & RO		.P		ART UNIT	PAPER NUMBER
	P.O. BOX 35 CANANDAIGUA		1352		1761	#10
					DATE MAILED:	04/22/99

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

	Application No. Applicant/a)		
	Application No. Applicant(s) 09/117,586 Bailey et al		
Office Action Summary	Examiner Group Art Unit 1761		
The MAILING DATE of this communication app	ears on the cover sheet beneath the correspondence address-		
Period for Response	·		
A SHORTENED STATUTORY PERIOD FOR RESPONSE IS MAILING DATE OF THIS COMMUNICATION.	S SET TO EXPIRE MONTH(S) FROM THE		
from the mailing date of this communication. - If the period for response specified above is less than thirty (30) date of the period for response is specified above, such period shall, by	R 1.136(a). In no event, however, may a response be timely filed after SIX (6) MONTHS, a response within the statutory minimum of thirty (30) days will be considered timelefault, expire SIX (6) MONTHS from the mailing date of this communication. ill, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). $7-7-9$		
Status Responsive to communication(s) filed on Prelim	1 11 1 -1 0 0 0		
	. Hand + 1 1 4-4 9		
☐ This action is FINAL.			
 Since this application is in condition for allowance excapacional accordance with the practice under Ex parte Quayle, 1 	pt for formal matters, prosecution as to the merits is closed in 935 C.D. 1 1; 453 O.G. 213.		
Disposition of Claims			
Claim(s) 45-111	is/are pending in the application.		
Of the above claim(s)	is/are withdrawn from consideration.		
\Box Claim(s) 45 50-54,57,58,67,73,8	is/are withdrawn from consideration. 3-85,96-98,99-102,103 is/are allowed. 109,109 109-72,74-79,86-89, is/are rejected. 109,109 109,109		
Claim(s) 46-48,49,55,56, 62-66,68,	39-72,74-79,86-89, 90-920/04767,116,111, is/are referred.		
□ Claim(s)	is/are objected to.		
□ Claim(s)	•		
Application Papers	requirement.		
.,	ing Povious PTO 048		
 □ See the attached Notice of Draftsperson's Patent Drave □ The proposed drawing correction, filed on 			
☐ The drawing(s) filed on is/are ob	• • • • • • • • • • • • • • • • • • • •		
☐ The specification is objected to by the Examiner.	•		
☐ The eath or declaration is objected to by the Everning			
☐ The oath or declaration is objected to by the Examine			
Priority under 35 U.S.C. § 119 (a)-(d) Acknowledgment is made of a claim for foreign priority All □ Some* □ None of the CERTIFIED copies □ received.	under 35 U.S.C. § 11 9(a)-(d). of the priority documents have been		
Priority under 35 U.S.C. § 119 (a)-(d) ✓ Acknowledgment is made of a claim for foreign priority ✓ All □ Some* □ None of the CERTIFIED copies	under 35 U.S.C. § 11 9(a)-(d). of the priority documents have been		
Priority under 35 U.S.C. § 119 (a)-(d) ✓ Acknowledgment is made of a claim for foreign priority ✓ All □ Some* □ None of the CERTIFIED copies □ received. □ received in Application No. (Series Code/Serial Nur	under 35 U.S.C. § 11 9(a)-(d). of the priority documents have been aber) nternational Bureau (PCT Rule 1 7.2(a)).		
Priority under 35 U.S.C. § 119 (a)-(d) ✓ Acknowledgment is made of a claim for foreign priority ✓ All □ Some* □ None of the CERTIFIED copies □ received. □ received in Application No. (Series Code/Serial Nur □ received in this national stage application from the	under 35 U.S.C. § 11 9(a)-(d). of the priority documents have been aber) nternational Bureau (PCT Rule 1 7.2(a)).		
Priority under 35 U.S.C. § 119 (a)-(d) Acknowledgment is made of a claim for foreign priority All Some* None of the CERTIFIED copies received. received in Application No. (Series Code/Serial Nur received in this national stage application from the *Certified copies not received: Attachment(s)	under 35 U.S.C. § 11 9(a)-(d). of the priority documents have been aber) nternational Bureau (PCT Rule 1 7.2(a)).		
Priority under 35 U.S.C. § 119 (a)-(d) □ Acknowledgment is made of a claim for foreign priority □ All □ Some* □ None of the CERTIFIED copies □ received. □ received in Application No. (Series Code/Serial Nur □ received in this national stage application from the *Certified copies not received:	under 35 U.S.C. § 11 9(a)-(d). of the priority documents have been aber) nternational Bureau (PCT Rule 1 7.2(a)).		

U. S. Patent and Trademark Office PTO-326 (Rev. 3-97)

Part of Paper No.

Application/Control Number: 09117586

Art Unit: 1761

DETAILED ACTION

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 46-49, 55, 56, 62-66, 68, 69-72, 74-79, 86-89, 90-95, 104-107, 110, 111 are rejected under 35 U.S.C. 103(a) as being unpatentable over Muller et al. or Shimoda et al. in view of Pedersen et al., Lucas et al., and Mueller et al.

Mueller et al. disclose a composition containing 5-methyl-9S)-tetrahydrofolic acid and 510 methyl-(6S) tetrahydrofolic acid. See abstract. Also, Shimoda et al. disclose a composition
containing vitamins in particular amounts and natural reduced folates (col. 4, lines 3-17, col. 7,
lines 61-65). Claims 49 and 56 differ from the references in the use of the folate with a nutritional
substance which is a vitamin in particular amounts. However, Pedersen et al. disclose that it is
known to use folacin in a potato flake. See col. 6, lines 1-12. Lucas et al. disclose that it is
known to use folic acid in an infant food. The specification discloses that these substances are
broken down in the digestive tract to the reduced form by an enzyme (col. 5, lines 9-16). If it is
known that folic acid and folacin are broken down to make the claimed compositions, then it is
obvious that such natural compounds can be also eaten in foods. The references, Pedersen et al.
and Lucas et al., are seen to be cumulative to show an improvement in the art. Applicants admit
in the specification that 5 formyl-tetrahydrofolic acid and 5 methyl-tetrahydrofolic acid have been

Application/Control Number: 09117586 Page 3

Art Unit: 1761

used in therapeutic doses. See page 5, lines 17-24. Mueller et al. disclose that their invention is an improvement of 6S and R forms with a natural form of 6S(col. 2, lines 3-7). Certainly, it would have been obvious to use a vitamin type substance with other foods, as food enrichment is well known and vitamins are rarely taken alone except as in pills. Therefore, it would have been obvious to one of ordinary skill in the art to use a reduced folate with other vitamins in the claimed composition.

The further limitations of claims 62-66 as to the addition of essential nutrients, the isomer being chirally pure and the particular natural isomers are seen to have been shown by the reference as above or are inherent characteristics. Therefore, it would have been obvious to add the ingredients of above to make the claimed composition.

Claims 68, 69, 74 and 75, 76 further require that the composition is only for particular animals and not pigs. However, nothing has been seen that the composition would not have worked for pigs which are also mammals, of course and no reason is seen for excluding them except to exclude the reference to Shimoda et al. The further limitation of adding less amounts of unnatural isomers of reduced folate is not seen to add patentable weight to the claims in that no reason is stated for such amounts nor is the addition of ascorbic acid to the composition which is a well known nutrient usually added for its known functions and nothing is seen that it adds any unobvious or unexpected results to the composition. The further limitations of the claims have been discussed above and are obvious for those reasons.

Application/Control Number: 09117586

Art Unit: 1761

Specification

1. The title of the invention is not descriptive. A new title is required that is clearly indicative of the invention to which the claims are directed. The title should also indicate the method.

Allowable Subject Matter

2. Claims 45, 50-54, 57, 58, 67, 73, 83-85, 96-98, 99-102, 103 are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Helen Pratt whose telephone number is (703) 308-1978. The examiner can normally be reached on Monday to Friday from 9:30 to 6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. David Lacey, can be reached on (703) 308-3535. The fax phone number for the organization where this application or proceeding is assigned is (703) 305-3602 (unofficial faxes), after final faxes 703 305 3599, and other official faxes 703 305 7718.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0661.

HELEN PRATT

PRIMARY EXAMINER

ART UNIT 1761